Skip to main content
Medical Reference · Condition Monograph

Primary Sclerosing Cholangitis

원발성 경화성 담관염

Primary sclerosing cholangitis has come to be defined as a disease in which chronic inflammation and scarring develop in the bile ducts, the passages through which bile flows, causing them to gradually narrow and become blocked.

History

Primary sclerosing cholangitis has come to be defined as a disease in which chronic inflammation and scarring develop in the bile ducts, the passages through which bile flows, causing them to gradually narrow and become blocked. Similar conditions were described from the mid-1800s, but at that time there was no way to see the bile ducts directly, so it was often understood within a broad category such as "bile stasis and cirrhosis of unknown cause." Later, as cholangiography and endoscopic techniques advanced, the characteristic appearance of bile ducts that "narrow and widen in places" was confirmed, and this established it more clearly as an independent disease.

Advances in diagnostic technology were directly linked to the development of the disease concept. In the past, endoscopic retrograde cholangiopancreatography was the representative test for examining the bile ducts, but because the procedure itself is invasive and carries a risk of complications, noninvasive imaging tests such as magnetic resonance cholangiopancreatography have recently moved to the center of diagnosis. Recent research summarizes that high-quality magnetic resonance cholangiopancreatography has become the "standard" for diagnosis, and endoscopic procedures are used selectively when there is a specific purpose, such as treatment or evaluation of strictures suspicious for cancer.

In the history of treatment, the fact that "there is no drug that reliably stops the progression of the disease" has long been a problem. When liver function deteriorates or complications develop, liver transplantation has effectively been the only treatment for long-term survival. Recent research shows that as investigational drugs in clinical trials have diversified and prognostic scores and imaging-based fibrosis measurement have advanced, there is a stronger trend toward refining "when and which patients should receive more intensive management."

Causes

The cause of primary sclerosing cholangitis has not yet been clearly defined as a single factor. However, it is considered to have a strong "autoimmune" or "immune-mediated" character and is often explained as a form in which environmental factors overlap with genetic predisposition to cause chronic inflammation in the bile ducts. Interestingly, it often does not respond clearly to immunosuppressants as typical autoimmune diseases do, so there is a strong view that it is a complex disease in which several pathways act together rather than a single simple mechanism.

The most important clue is its strong association with inflammatory bowel disease. A considerable proportion of patients with primary sclerosing cholangitis also have ulcerative colitis, and some also have Crohn disease. The concept of the "gut-liver axis," in which intestinal inflammation and changes in the gut bacterial environment alter the signals transmitted to the liver and can sustain bile duct inflammation, has become a core pillar of explaining the cause.

Recent research summarizes that gut microbial imbalance, entry of bacterial components into the liver due to impaired intestinal barrier function, changes in bile acid composition, and senescence responses of bile duct cells may be involved in disease progression. The direction in which an individual's immune response becomes fixed is considered an important variable in determining whether the disease develops.

Genetic Epidemiology

Primary sclerosing cholangitis is not a disease determined by a single gene, but it is understood as a disease in which genetic predisposition is clearly involved. Associations with the human leukocyte antigen (HLA) family, which determines the direction of immune responses, have been repeatedly reported, and this is explained as a factor that increases "the likelihood that, when intestinal inflammatory signals come in, the immune response will tilt toward a form that attacks the bile ducts." However, having a genetic predisposition does not mean the disease will necessarily develop. Recent research summarizes that genetics explains only part of the risk and that environmental factors may account for a large share.

An important practical point in genetic epidemiology is family history. If close family members have inflammatory bowel disease or primary sclerosing cholangitis, the risk may be somewhat higher, so this serves as a clue for more active evaluation when there are abnormal liver test results or unexplained findings of bile stasis.

Therefore, it is natural to regard genetics as a factor that raises "susceptibility," and actual onset and progression as the result produced jointly by the gut environment, failure of immune response regulation, and secondary damage due to bile stasis. In general, screening with genetic testing has not become established as a standard approach.

General Epidemiology

Primary sclerosing cholangitis is not a common disease, but it shows relatively distinct features in certain groups. It is usually diagnosed in people in their 30s to 40s, and many reports indicate it is more common in men. Because it frequently coexists with inflammatory bowel disease, it is an important differential diagnosis when cholestatic liver test abnormalities are seen in patients with inflammatory bowel disease.

An especially important epidemiological aspect is cancer risk. Primary sclerosing cholangitis increases the risk of cholangiocarcinoma, gallbladder cancer, and liver cancer, and when inflammatory bowel disease is also present, the risk of colorectal cancer increases as well. Therefore, the "disease burden" of primary sclerosing cholangitis must be evaluated to include not only progression to cirrhosis but also cancer surveillance, early detection, and the possibility of cancer treatment.

Recent research summarizes that many patients are asymptomatic at diagnosis and are often found through abnormal liver test results during follow-up tests for inflammatory bowel disease. In addition, the course of the disease varies greatly from person to person: some progress relatively slowly, while others experience recurrent cholangitis, dominant strictures, or rapid progression of fibrosis.

Pathogenesis

The pathogenesis of primary sclerosing cholangitis can be understood as "a process in which chronic inflammation and fibrosis surrounding the bile ducts repeat, narrowing the bile ducts, and eventually bile flow is blocked and the liver is damaged." Bile is necessary for fat digestion and the excretion of waste products, but when bile stagnates, it becomes toxic to the bile ducts and liver cells, creating a vicious cycle in which inflammation and scarring worsen further. The gut-liver axis is often mentioned as a central mechanism. When there is inflammation in the intestine or the balance of gut microbes is disrupted, bacterial components and immune cell signals can enter the liver through the portal vein and excessively stimulate the immune response around the bile ducts.

Recent research suggests that senescence responses of bile duct cells and senescence-associated secreted substances may play a role in intensifying inflammation and fibrosis in surrounding tissues. In addition, both innate and adaptive immunity are involved in the immune response, and certain antibodies are sometimes detected on testing, but these alone cannot explain the cause of the disease.

As a result, there is a strong trend toward explaining the pathogenesis with a multipathway model in which "immune abnormalities + the gut environment + bile stasis" reinforce one another. The complex interaction of these multiple factors is understood as the key background that produces different courses in different individuals.

Symptoms

Primary sclerosing cholangitis commonly has no symptoms at first. Therefore, it is often discovered incidentally when liver test results come back abnormal during a health checkup or follow-up tests for inflammatory bowel disease. When symptoms appear, nonspecific symptoms such as fatigue, itching, and discomfort in the upper right abdomen are common. When bile stasis becomes severe, jaundice, in which the skin and eyes turn yellow, can develop, the urine may become darker, and the stool may become lighter in color.

When the bile ducts are severely blocked or a bacterial infection is present, acute cholangitis can develop, with fever, chills, abdominal pain, and jaundice appearing together, and if it recurs, hospital treatment may be needed. If the disease progresses and cirrhosis develops, complications of cirrhosis such as ascites, leg edema, variceal bleeding, and changes in consciousness can appear. In addition, if bile does not pass into the intestine well, fat absorption decreases, which can cause weight loss, diarrhea, fatty stools (steatorrhea), and deficiency of fat-soluble vitamins.

Recent research summarizes that because itching, sleep disturbances, and fatigue can greatly reduce quality of life, it is important to actively make the symptoms themselves a goal of treatment.

Signs

On blood tests, cholestatic liver test abnormalities are an important clue. A pattern of elevated alkaline phosphatase and gamma-glutamyl transferase is especially common, and as the disease progresses, it may be accompanied by elevated bilirubin. However, because the values fluctuate greatly, it is difficult to judge the course definitively from "a single value." Imaging tests provide the key signs. On magnetic resonance cholangiopancreatography or endoscopic cholangiography, findings of bile ducts that narrow and widen in multiple places, with irregular strictures and dilations, may be seen.

On examination, findings such as jaundice, scratch marks, enlargement of the liver and spleen, and, in advanced cases, ascites or leg edema may be observed. If there is impaired fat absorption, weight loss or signs of nutritional deficiency may accompany these. A variant that involves only the small bile ducts may look normal on imaging, and in this case a biopsy is helpful.

Recent research summarizes that noninvasive tests that measure the stiffness of the liver (ultrasound elastography, magnetic resonance elastography, etc.) can help estimate the degree of fibrosis and predict prognosis.

Screening

Primary sclerosing cholangitis is not common enough in the general population to warrant screening tests. Instead, "suspicion and evaluation" focused on high-risk groups becomes the core of screening. The most important high-risk group is patients with inflammatory bowel disease. In particular, if cholestatic liver test abnormalities persist in a person with ulcerative colitis, primary sclerosing cholangitis is suspected and imaging tests are considered. In addition, once primary sclerosing cholangitis is diagnosed, it is important to check for coexisting inflammatory bowel disease with colonoscopy even if there are no intestinal symptoms.

Screening is also linked to cancer surveillance. Because primary sclerosing cholangitis carries a high risk of cholangiocarcinoma, gallbladder cancer, and colorectal cancer, after diagnosis, early detection is pursued through regular imaging, marker tests, colonoscopy, and so on.

Recent research emphasizes an approach of performing colonoscopy and biopsy at the time of diagnosis to check for coexisting inflammatory bowel disease, and re-evaluating at regular intervals thereafter. Although there is still debate about which tests and intervals are best, imaging-based surveillance is becoming an important pillar in practice.

Diagnosis

The diagnosis is made after ruling out other causes of "secondary sclerosing cholangitis," by combining bile duct imaging findings with clinical findings and blood tests. The key is the cholangiographic findings. Currently, magnetic resonance cholangiopancreatography is often chosen as the first-line diagnostic test because it is noninvasive and highly accurate. Endoscopic retrograde cholangiopancreatography is gradually being used less for diagnostic purposes and is often performed when there is a "purpose," such as treatment of cholangitis, dilation and drainage of dominant strictures, or cytology of strictures suspicious for cancer.

Blood tests confirm the cholestatic pattern and assess liver function and the risk of complications. Autoantibodies or immunoglobulin abnormalities may be present, but these are not specific in themselves. Differentiation from other diseases such as immunoglobulin G4-related cholangitis is also important, so if necessary, related tests and the clinical response are considered together.

A biopsy is not essential in all patients, but it plays an important role when a small-duct variant is suspected or when an overlap with autoimmune hepatitis is suspected. Accurate differential diagnosis plays a key role in determining the direction of treatment.

Treatment

To date, there is no drug that reliably stops the progression of the disease. Therefore, treatment is broadly divided into 1) management of symptoms and complications, 2) endoscopic treatment of bile duct strictures, 3) cancer surveillance, and 4) evaluation for liver transplantation. A representative goal of symptom treatment is controlling itching. Drugs such as bile acid sequestrants are used, and if necessary, other itch treatments are applied step by step. If there is deficiency of fat-soluble vitamins due to bile stasis, supplementation is needed. If recurrent cholangitis develops, antibiotic treatment is important.

Among drugs, ursodiol (ursodeoxycholic acid) is controversial. Some guidelines mention that moderate doses may be selectively considered, while other guidelines consider the evidence of a definite survival benefit insufficient. If dominant strictures or cholangitis recur, endoscopic procedures can widen or drain the bile ducts to reduce symptoms and prevent infection. When end-stage liver disease, recurrent infections, or progressive complications develop, liver transplantation becomes the most definitive long-term treatment.

Recent research summarizes that participation in clinical trials is an important option and that various targeted drugs are under development. However, because the disease can recur even after transplantation, long-term follow-up is needed.

Prognosis

The prognosis varies greatly between individuals. Some people live without symptoms for a long time, but others need a transplant due to recurrent cholangitis, dominant strictures, or rapid progression of fibrosis. In general, it is a progressive disease over the long term, and over time it can lead to biliary cirrhosis and liver failure. A major variable that worsens the prognosis is cancer. Cholangiocarcinoma is known to be one of the most lethal complications of primary sclerosing cholangitis, and it can be found even in the early period after diagnosis.

In addition, because the risks of gallbladder cancer, liver cancer, and colorectal cancer are also high, prognostic assessment must consider the risk of cancer development as well as liver function. Recent research summarizes the observation that cases in which alkaline phosphatase remains relatively low may be associated with a better course, and that noninvasive tools such as elastography and magnetic resonance-based scores can help predict prognosis.

However, because it is difficult to determine an individual's future definitively with a single test, repeated assessment is needed. Comprehensive prognostic management that includes cancer risk is the core of care for primary sclerosing cholangitis.

Prevention

There is no definite method of "primary prevention" for primary sclerosing cholangitis. Instead, realistic prevention is secondary prevention, that is, early detection and prevention of complications. First, when cholestatic liver test abnormalities appear in patients with inflammatory bowel disease, it is important to keep the possibility of primary sclerosing cholangitis in mind and diagnose it early through imaging tests. Second, after diagnosis, surveillance for cholangiocarcinoma, gallbladder cancer, and colorectal cancer becomes the de facto prevention strategy. Early detection is pursued through regular imaging tests, gallbladder ultrasound, and colonoscopy, and if there are suspicious findings, a detailed evaluation is performed immediately.

Third, prevention of cholangitis and prevention of nutritional deficiencies are important. When fever, jaundice, and abdominal pain occur together, they should be evaluated without delay so that cholangitis can be treated quickly, and fat-soluble vitamin deficiency should be checked and supplemented. If cirrhosis develops, worsening is reduced in the same way as for cirrhosis of other causes, through abstinence from alcohol, avoidance of hepatotoxic drugs, vaccination, and regular follow-up.

Recent research mentions treatments targeting the gut-liver axis and microbiome-based approaches as possibilities that could broaden the boundary between prevention and treatment, but in current practice, the center of prevention is still "early diagnosis + surveillance for complications."

This content is provided for general medical information only and does not replace individual diagnosis or treatment. If symptoms persist, please consult a medical professional.